AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ROQUEFORT THERAPEUTICS PLC

AGM Information Dec 13, 2021

5061_dva_2021-12-13_2fadaec2-fdb8-4e68-9de9-13ad78e4dba6.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 4696V

Roquefort Investments PLC

13 December 2021

13 December 2021

Roquefort Investments plc

("Roquefort Investments" or the "Company")

Results of General Meeting

Roquefort Investments (LSE:ROQ), the London listed investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector, is pleased to announce that at the Company's General Meeting held earlier today, all resolutions proposed were duly passed.

The resolutions were put to shareholders via a poll, the results of which were as follows:

Resolution Poll Results
For Against Abstain Discretionary Total
1 Shares 1,800,000 - - - 1,800,000
% 100% - - - 100%
2 Shares 1,800,000 - - - 1,800,000
% 100% - - - 100%
3 Shares 1,800,000 - - - 1,800,000
% 100% - - - 100%
4 Shares 1,800,000 - - - 1,800,000
% 100% - - - 100%

The total number of ordinary shares in issue on 9 December 2021, the deadline for casting votes by proxy in advance of the General Meeting, was 36,900,000 shares.  4.88% of voting capital was instructed in respect of the resolutions put to the Genaral Meeting.

Enquiries:

Roquefort Investments plc
Stephen West (Chairman) +44 (0)20 3290 9339
Buchanan (Public Relations)

Ben Romney / Jamie Hooper

Optiva Securities Limited (Broker)
+44 (0)20 7466 5000
Christian Dennis +44 (0)20 3411 1881

For further information on Roquefort Investments, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

LEI: ‎254900P4SISIWOR9RH34

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMBXBDDLBBDGBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.